Table 2.
Summary of specificity of cell lines
| Recognition of T2 cell lines | ||||||
|---|---|---|---|---|---|---|
| T2 | T2-B27 | T2-B27-TAP | Inhibition | Responses to EBV-LCL | Molecule recognized | |
| SB2 | – | + | +++ | W6/32 | No | HLA-B51. In the absence of TAP recognizes a B27-derived peptide presented by B51 |
| LB23 | – | + | +++ | W6/32, MA2.1 | Yes A2+, B27+ LCL A2+ B8+ LCL | HLA-A2 presenting a B27-derived peptide whose expression is enhanced by TAP |
| CC26 | – | + | – | W6/32, MA2.1 | No | HLA-A2 presenting a B27-derived peptide only present on TAP-deficient cells |
| CC18 | – | + | – | W6/32, MA2.1 | Yes. Weak responsesto a limited number of A2+, B27+ or A2+ B8+ LCL | HLA-A2 presenting a B27-derived peptide preferentially expressed on TAP-deficient cells |
| MM15 | + | + | ++ | W6/32, MA2.1 | No | HLA-A2 on T2 cells |
| MM12 | + | + | – | W6/32 | Yes. No conserved pattern of recognition | Possible A2-derived peptide presented by more than one HLA class I allele |
EBV-LCL, Epstein–Barr virus-transformed lymphoblastoid cell line; HLA, human leucocyte antigen; T2-B27, T2 cell line transfected with HLA-B*2705; T2-B27-TAP, T2-B27 reconstituted with TAP1 and TAP2.